Differences in Nervous Autonomic Control in Response to a Single Session of Exercise in Bodybuilders Using Anabolic Androgenic Steroids

by

Jefferson Fernando Coelho Rodrigues Júnior1,2, Alexandre Sérgio Silva3,4, Glêbia Alexa Cardoso3,4, Valmir Oliveira Silvino1,2,5, Acácio Salvador Veras-Silva1, Fabio Yuzo Nakamura6, Marcos Antonio Pereira dos Santos1,2,5

Considering the role of autonomic nerve activity in blood pressure control, this study aimed to investigate the cardiac autonomic nerve responses after an aerobic exercise session in Anabolic Androgenic Steroids (AAS) users. Twenty men (AAS, n = 9; control group, n = 11) performed an aerobic exercise session (60 min, 70 to 80% of HRmax). Heart rate variability (HRV) was assessed before and during a 60-min post-exercise recovery period. RMSSD (root mean square successive difference of the RR intervals) and the LF/HF ratio (low frequency/high frequency spectra) were also evaluated. The Student’s t-test for independent samples was used to compare differences between initial group characteristics. Repeated measures ANOVA was used to compare pre- and post-exercise HRV recovery (p < 0.05). AAS had a lower SDNN (standard deviation of the intervals) (40.8 ± 16.8 vs. 71.6 ± 24.7 ms; p = 0.04, d = 1.4) and a higher LF/HF (3.4 ± 2.1 vs. 1.8 ± 0.9%; p = 0.03, d = 0.9) before exercise. AAS and controls had similar RMSSD (14.0 ± 15.8 vs. 18.9 ± 12.1 ms; p = 0.20) and a LF/HF (2.8 ± 1.6 vs. 2.4 ± 1.2 ms; p = 0.41) immediately post-exercise. The between-groups comparison revealed a higher HF/LF at 30 min (4.3 ± 1.4 vs. 2.5 ± 1.3%; p = 0.008, d = 1.3) and 60 min (5.0 ± 2.2 vs. 2.3 ± 0.8%; p = 0.001, d = 1.6) for the AAS group in the recovery time. This study demonstrated impaired parasympathetic activity at rest and immediately after the exercise session as an adverse effect of AAS usage, but similar behavior regarding the restoration of sympathetic activity.

Key words: physical exercise, anabolic agents, autonomic nervous system, heart rate variability.

Introduction

The non-medical use of Anabolic Androgenic Steroids (AAS) has been considered a widespread public health problem in recent decades (Leifman et al., 2011) due to the dramatic increase in the prevalence rate of its use, not only among elite athletes, but also among “recreational” exercise practitioners (Kanayama et al., 2018). A meta-regression of 187 studies stated that the overall prevalence rate was 21.7% in the

---

1 - Department of Biophysics and Physiology, Ministro Petrônio Portella Campus, Federal University of Piauí (UFPI), Teresina, Brazil.
2 - Nucleus of Study in Physiology Applied to Performance and Health (NEFADS), Federal University of Piauí (UFPI), Teresina, Brazil.
3 - Laboratory of Applied Studies in Physical Training to Performance and Health - LETFADS, Department of Physical Education, Federal University of Paraíba, João Pessoa, Brazil.
4 - Associate Graduate Program in Physical Education - LIPE / UFPI, Department of Physical Education, Federal University of Paraíba, João Pessoa, Brazil.
5 - Rede Nordeste de Biotecnologia (RENORBIO) post-graduation program, Federal University of Piauí (UFPI), Teresina, Brazil.
6 - Research Center in Sports Sciences, Health Sciences and Human Development, CIDESD, University of Maia, ISMAI, Maia, Portugal.

Authors submitted their contribution to the article to the editorial board.
Accepted for printing in the Journal of Human Kinetics vol. 80/2021 in October 2021.
Middle East, 4.8% in South America, 3.8% in Europe, 3.0% in North America, 2.6% in Oceania, 2.0% in Africa, and 0.2% in Asia, significantly greater among men, adolescents, and recreational athletes (Sagoe et al., 2014).

Chronic and supraphysiological use of AAS can promote side effects including infertility (Christou et al., 2017) and gynecomastia (Rahmema et al., 2015) in men, and virilization and alteration in the libido in women (Rocha et al., 2014). In addition, it is associated with liver injury (Schwingel et al., 2011), sudden death (Frati et al., 2015; Nieschlag and Vorona, 2015), increased aggressiveness (Maior et al., 2013), and even death from urban violence due to increased aggressiveness (Choi and Pope, 1994). The indiscriminate use of AAS can also lead to several cardiometabolic disorders, such as dyslipidemia, infarction, stroke, inhibition of angiogenesis, systemic inflammation, and vascular dysfunction (Santos et al., 2014; Vanberg and Atar, 2010). These effects explain the increase in blood pressure to hypertensive levels, which is regarded as another notorious AAS side effect (Rodrigues-Junior et al., 2017).

Furthermore, the impairment of the response to post-exercise hypotension as a new side effect of the use of AAS has recently been demonstrated (Rodrigues-Junior et al., 2017). In the aforementioned study, AAS users did not reduce blood pressure after an aerobic exercise session. However, the possible associated mechanisms were not presented. There is also evidence that AAS promote a reduction in the parasympathetic resting activity in animals (Pereira-Junior et al., 2006) and humans (Vanderlei et al., 2009). Hence, we raised the hypothesis that users of AAS may present dysfunction of autonomic nervous activity after an aerobic exercise session. Thus, the present study was designed to investigate the acute effect of aerobic exercise on heart rate variability (HRV) among bodybuilders using AAS.

**Methods**

**Participants**

Nine AAS male users (21.8 ± 2.8 years old) and eleven male controls (22.1 ± 4.5 years old) were recruited for this study. They performed strength exercises for bodybuilding competition at the professional level. Volunteers trained at least six times a week and had been practicing bodybuilding for at least two years. None of the participants presented any chronic degenerative disease, nor did any of them use antihypertension medicines or nutritional supplements. No smokers or alcohol consumers were included as volunteers for this study. Participants who refused or presented difficulties performing the exercise session were excluded from the study.

The AAS group had been using AAS at baseline for at least 2 years, ranging from 2 to 6 complete cycles. The average weekly AAS dosage was 300 ± 161.9 mg. The most widespread AAS used by participants were testosterone propionate (33.3%), testosterone propionate + stanozolol (11.1%), testosterone propionate + oxandrolone (22.2%), dianabol (22.2%) and testosterone enanthate + drostanolone propionate + boldenone (11.1%).

**Experimental Protocol**

All volunteers were anthropometrically evaluated and instructed to refrain from exercise for 48 h before the experiment test trial, as well as to avoid the intake of supplements and food with stimulants, such as coffee, tea, soda, energy drinks, and chocolates. HRV measurements were performed at rest, immediately after the exercise session, and in the recovery period every 10 min until completing the 60 min recovery period. The entire protocol is shown in Figure 1.

The exercise protocol was performed between 2 and 4 PM. One aerobic exercise session was performed on a treadmill (ProAction BH fitness, Puerto del Carmen, Spain). Firstly, volunteers began with a warm-up run on the treadmill for 3 min at self-chosen intensity, considered mild by the volunteers (<60% of HRmax). Immediately after the warm up, they gradually increased the speed by 1% every minute until the prescribed heart rate (HR) was reached (between 70 and 80% of HRmax). Once the HR was within the prescribed zone, the treadmill speed remained unchanged until the end of 60 min of exercise, according to recommendations for this population (American College of Sports Medicine, 2002).

The HR was measured with a V800 heart rate monitor (Polar® Electro Oy, Kempele, Finland), previously validated to record beat-to-beat heart rate and heart rate variability analysis.
by Giles et al. (2016). For pre- and post-exercise measures, participants remained seated in a quiet environment with temperature between 24 and 27°C. Autonomic activity was determined by recording the variability of the R-R heart rate intervals under resting conditions 5 min before exercise, immediately after exercise and in the recovery period at the 10th, 20th, 30th, 40th, 50th and 60th min. Before each evaluation, there was a 5-min period of R-R interval stabilization (except for measurement immediately after exercise). The subsequent five minutes were extracted from the monitor and converted into text using Polar ProTrainer software. The initial and final records were discarded, thus only 300 heart beats were analyzed by HRV analysis software.

HRV was measured according to linear methods (time and frequency). Time domain measures included RR (interval means), SDNN (standard deviation of the intervals) and RMSSD (square root of the mean squared difference between adjacent RR intervals), expressed in ms. For the frequency domain, analysis included the LF/HF - ratio spectral components of low frequency (LF) and high frequency (HF). They were calculated in order to indirectly reflect a shift to sympathetic or parasympathetic predominance. The HF component acts in HRV reflecting parasympathetic modulation, whereas the LF component includes sympathetic and parasympathetic function.

Statistical analysis

The data are presented as mean ± standard deviation of the mean. The normality and homogeneity of the data were analyzed via Shapiro-Wilk and Levene’s tests, respectively. Since HRV did not present normal distribution, natural logarithmic (ln) transformation was employed. An independent Student’s t-test was used to compare differences between initial group characteristics. Repeated measures ANOVA was used to compare pre- and post-exercise HRV recovery. Cohen’s d effect size was used to calculate the magnitude of the difference. Values of 0–0.19, 0.20–0.49, 0.50–0.79, and >0.80 were considered trivial, small, moderate and large, respectively (Cohen, 1988). The level of significance was established at $p < 0.05$. The entire statistical analysis was performed using the SPSS version 20.0 statistical software (SPSS, Inc., Chicago, IL, USA).

Results

Data regarding resting characteristics are presented in Table 1. Participants were statistically similar in age, body mass, body height, and VO$_2$max, differing only in body mass index (BMI) ($p = 0.02$). At rest, the AAS group had lower diastolic blood pressure ($p = 0.01$) and similar systolic blood pressure, mean arterial pressure, and HR. The AAS group presented lower initial values for the standard deviation of the interval (SDNN) ($p = 0.04$) variables and higher initial value of the LF/HF ($p = 0.03$) than the control group.

Figure 2 shows HR, RMSSD, SDNN and LH/HF values before, after and during the recovery. The aerobic session caused an increase in the HR with recovery in the post-exercise period. However, AAS users presented a consistently higher HR than the control group at all times at 0, 30, 50, and 60 min after exercise (Figure 2, Panel A).

The aerobic session significantly reduced the RMSSD both in the AAS ($31.1 \pm 21.7$ to $14.0 \pm 15.8$ ms; $p = 0.005$, $d = 0.9$) and in the control group ($46.9 \pm 21.5$ to $18.9 \pm 12.1$ ms; $p = 0.002$, $d = 1.6$) compared to before exercise (Figure 2, Panel B). The response to exercise and recovery was similar in both groups, despite the descriptively lower values for AAS users in all measurements performed (Figure 2, Panel B). As for the SDNN (Figure 2, Panel C) variable, there were significant differences between the experimental and control groups before and in the 10th min of post-exercise recovery.

The LF/HF ratio did not change immediately after the cessation of exercise considering rest values in both groups. However, during the recovery period, this balance underwent a slight and gradual increase in the AAS group up to 40 min and remained at these values until the end of the recovery session. As a result, the values were significantly higher than those of the control group at the 30th and 60th min after exercise.
### Table 1

Initial values of body composition, blood pressure and heart rate variability of the study participants (n=20).

| Variables                             | Control (n=11) | AAS (n=9) | \( p \) | \( d \) |
|---------------------------------------|----------------|-----------|--------|--------|
| Age                                   | 22.1 ± 4.5     | 21.8 ± 2.8| 0.86   | 0.08   |
| Body mass (kg)                        | 75.5 ± 11.8    | 82.2 ± 6.9| 0.19   | 0.69   |
| Body height (m)                       | 1.8 ± 0.1      | 1.7 ± 0.1 | 0.30   | 1.00   |
| BMI (kg·m\(^{-2}\))                  | 24.5 ± 2.9     | 27.0 ± 1.8| 0.02   | 1.04   |
| SBP (mmHg)                            | 128.9 ± 14.1   | 125.7 ± 10.4| 0.57  | 0.26   |
| DBP (mmHg)                            | 76.8 ± 10.2    | 66.4 ± 5.7 | 0.01* | 1.26   |
| MBP (mmHg)                            | 94.1 ± 10.8    | 86.1 ± 6.5 | 0.06  | 0.89   |
| \( VO_2_{\text{max}} \) (mL·kg\(^{-1}\)·min\(^{-1}\)) | 52.6 ± 3.8     | 49.3 ± 2.4 | 0.06  | 1.04   |
| RHR (bpm)                             | 73.7 ± 8.6     | 82.8 ± 13.6| 0.10  | 0.79   |
| RR (ms)                               | 808.0 ± 107    | 709.9 ± 160| 0.13  | 0.72   |
| SDNN (ms)                             | 71.6 ± 24.7    | 40.8 ± 16.8| 0.04* | 1.45   |
| RMSSD (ms)                            | 46.9 ± 21.5    | 32.1 ± 21.7| 0.15  | 0.68   |
| LF (ms\(^2\))                         | 561.5 ± 324.7  | 485.7 ± 216.3| 0.29 | 0.27   |
| HF (ms\(^2\))                         | 378.0 ± 267.6  | 206.2 ± 162.9| 0.09  | 0.77   |
| LF/HF (%)                             | 1.8 ± 0.9      | 3.4 ± 2.1 | 0.03* | 0.99   |

Data are: BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; MBP, mean blood pressure; \( VO_2_{\text{max}} \), maximum oxygen uptake; RHR, resting heart rate; RR, interval means; SDNN, standard deviation of the intervals; RMSSD, root mean square successive difference of the RR intervals; LF, low frequency spectrum; HF, high frequency spectrum; LF/HF, ratio of spectral components of low frequency (LF) and high frequency (HF). * Significant difference Control vs. AAS (\( p < 0.05 \)).

### Figure 1

Schematic view of the exercise and evaluation protocol. HR, heart rate; HRV, heart rate variability.
Discussion

This study provides evidence of differences in nervous autonomic control at rest and immediately after aerobic exercise in AAS users, but a similar recovery for both AAS and control groups. As far as we know, only few studies have investigated the behavior of the post-exercise autonomic system in AAS users. Resting autonomic dysfunction has already been reported in studies with animal and human models. Studies using animal models found significant reductions in parasympathetic activity and increased cardiac sympathetic modulation after chronic administration of high doses of AAS (Marocolo et al., 2013; Pereira-Junior et al., 2006). This behavior was also observed in two studies carried out with humans using supraphysiological doses (Maior et al., 2013; Neto et al., 2017).

Although there was no significant difference in the HR at rest, we observed that...
individuals in the AAS group had higher HR values (12.3%) compared to those of the control group (82.8 vs. 73.7 BPM, respectively). That has significant clinical relevance since a relationship between HR values and acute myocardial infarction has been reported (Berton, 2002), in addition to a greater chance of atherosclerotic plaque rupture in the coronary artery in men with HR > 80 BPM (Heidland and Strauer, 2001). After exercise, the HR showed a quick (although incomplete) decline in the first minutes of recovery with eventual return to pre-exercise levels, with greater reduction in the control group, corroborating with other studies (Al Haddad et al., 2011; Stanley et al., 2013).

Likewise, the AAS group presented lower HRV (13.9%) at rest (709.9 ± 160) when compared to the control group (808.0 ± 107). Previous studies have already reported autonomic dysfunction at rest, both in animal models and humans. Maior et al. (2013) showed that R-R interval levels at rest were lower and the LF/HF ratio was higher in the AAS group compared to control subjects. This is probably due to an increase in the sympathetic activity and a decrease in the parasympathetic activity. Despite the fact that the previous study differed from ours regarding the aerobic exercise test adopted (cycle ergometer), time of AAS administration (5 vs. 2 years), and the dosage per week (410 ± 78.6 vs. 300 ± 161.9 mg), their data are similar to ours regarding RMSSD and the LF/HF.

AAS users have lower HRV and cardiac remodeling at rest compared to non-users (Seara et al., 2019), which lead to a higher cardiovascular risk and sudden cardiac death (Hoshi et al., 2021). For the SDNN variable, the AAS group showed significantly lower values (42.9%) than the control group ($p = 0.04$). Studies indicate that SDNN values below 70 ms present an increased risk of developing cardiovascular diseases (La Rovere et al., 1998). Individuals with SDNN <50 ms, as observed in our study, are 5.3 times more likely to die (Hoshi et al., 2021; Kleiger et al., 1987). To the best of our knowledge, this is the first study to evaluate HRV in bodybuilders during a 60-min post aerobic exercise recovery period. A similar study using 22 recreational athletes observed lower values before and after exercise for the RR, RMSSD, LF and HF variables in AAS users (Maior et al., 2013). However, they assessed HRV only 5 minutes post-exercise.

Figure 2 shows tachograms representative of the AAS and control groups, at rest and during 60 min of recovery. The control group showed a greater reduction in SDNN (73.4%) in the first 10 min of recovery compared to the AAS group (52.4%). However, the control group returned to pre-exercise values more quickly, in the first 20 min of recovery. During recovery, SDNN of the AAS group remained similar to that of the control group, which shows that the reduction in parasympathetic activity can occur during and at the end of exercise in AAS users, but returns to the resting state after 20 min of recovery regardless of the use of AAS.

HRV analysis has been widely used to evaluate autonomic function in several sports disciplines (Picabea et al., 2021; Ravé et al., 2020). During exercise, there is an increase in sympathetic modulation and a reduction in vagal modulation. However, soon after exercise, a return to pre-exercise values is expected. The average value of the RMSSD index in the AAS group after exercise was higher (by 22.2%) than that of the control group (26.34 and 20.49, respectively). In addition, the control group showed total recovery of the vagal index (RMSSD) in the first 20 min of recovery, while the AAS group recovered completely only 60 min after the start of the recovery.

The LF component, related to both vagal modulation and sympathetic modulation, was lower (by 13.5%) in the AAS (485 ms²), when compared to the control group (561 ms²). This is an indicator of sympathetic hyperactivity, since sympathetic activity contributes to by approximately 15% more than vagal activity for this index (Piccirillo et al., 2009). In addition, this lower LF power may reflect a lower parasympathetic HF activity, which was by 45.5% lower in AAS users.

Parasympathetic control, measured by HF power, was lower among users of AAS, apparently as a result of reduced vagal reactivation (delay in parasympathetic control), as previously described in other studies (Cole et al., 1999; Santos et al., 2014). In addition, AAS users had an LF/HF ratio higher than that of the control group (by 47.1%), which is an indicator of an increased risk of cardiovascular events, corroborating other authors (Santos et al., 2014).

Since vagal imbalance is associated with
increased blood glucose and degenerative chronic diseases, an increase in the sympathetic activity can affect several physiological responses (Maior et al., 2013; Neto et al., 2017). In fact, this study is an extension of research in which we demonstrated impaired systolic post-exercise hypotension (PEH) as a new adverse effect of AAS usage (Rodrigues Junior et al., 2017).

Sympathetic activity is one of the main mechanisms to promote the PEH, which is impaired by the usage of AAS, as we previously reported (Rodrigues Junior et al., 2017). In the present study, we demonstrated that the LF/HF balance can impair PEH in AAS users. Previous research indicates that the increase in parasympathetic activity and endothelial-mediated dilation after exercise play an important role in PEH (Halliwill, 2001). Therefore, we can assume that lower parasympathetic activity and the absence of PEH occur concomitantly in AAS users.

In conclusion, this study verified differences in cardiac autonomic responses at rest and after aerobic exercise between AAS users and controls. AAS users had autonomic dysfunction and recovered less efficiently, but only at the end of the exercise. Further research is recommended to verify whether sympathetic hyperactivity or parasympathetic hypoactivity is the cause of these adverse effects of the use of AAS.

**Acknowledgements**

The authors would like to thank all volunteers who participated in this study.

**References**

Al Haddad, H., Laursen, P., Chollet, D., Ahmaidi, S., & Buchheit, M. (2011). Reliability of resting and postexercise heart rate measures. *International Journal of Sports Medicine, 32*(8), 598.

American College of Sports Medicine. Progression models in resistance training for healthy adults. *Medicine & Science in Sports & Exercise*, 2002; *34*(1): 364–380

Berton, G. S., Cordiano, R., Palmieri, R., Gheno, G., Mormino, P., Palatini, P. (2002). Heart rate during myocardial infarction: Relationship with one—year global mortality in men and women. *Canadian Journal of Cardiology*, 18(5), 495.

Choi, P. Y., & Pope, H. G. (1994). Violence toward women and illicit androgenic-anabolic steroid use. *Annals of Clinical Psychiatry*, 6(1), 21-25.

Christou, M. A., Christou, P. A., Markozannes, G., Tsatsoulis, A., Mastorakos, G., & Tigas, S. (2017). Effects of anabolic androgenic steroids on the reproductive system of athletes and recreational users: a systematic review and meta-analysis. *Sports Medicine, 47*(9), 1869-1883.

Cohen J. Statistical Power Analysis for the Behavioral Sciences, 1988; (2nd ed.) Hillsdale: Routledge

Cole, C. R., Blackstone, E. H., Pashkow, F. J., Snader, C. E., & Lauer, M. S. (1999). Heart-rate recovery immediately after exercise as a predictor of mortality. *New England Journal of Medicine, 341*(18), 1351-1357.

Fineschi, V., Riezzo, I., Centini, F., Silingardi, E., Licata, M., Beduschi, G., & Karch, S. B. (2007). Sudden cardiac death during anabolic steroid abuse: morphologic and toxicologic findings in two fatal cases of bodybuilders. *International Journal of Legal Medicine, 121*(1), 48-53.

Frati, P., P Busardo, F., Cipolloni, L., De Dominicis, E., & Fineschi, V. (2015). Anabolic androgenic steroid (AAS) related deaths: autopic, histopathological and toxicological findings. *Current Neuropharmacology, 13*(1), 146-159.

Giles, D., Draper, N., & Neil, W. (2016). Validity of the Polar V800 heart rate monitor to measure RR intervals at rest. *European Journal of Applied Physiology, 116*(3), 563-571.

Halliwill, J. R. (2001). Mechanisms and clinical implications of post-exercise hypotension in humans. *Exercise and Sport Sciences Reviews, 29*(2), 65-70.

Heidland, U. E., & Strauer, B. E. (2001). Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. *Circulation, 104*(13), 1477-1482.

Hoshi, R. A., Santos, I. S., Dantas, E. M., Andreão, R. V., Mill, J. G., Lotufo, P. A., & Bensenor, I. (2021). Reduced heart-rate variability and increased risk of hypertension—A prospective study of the ELSA-
Brasil. *Journal of Human Hypertension*, 1-10.

Kanayama, G., Pope Jr, H. G., & Hudson, J. I. (2018). Associations of anabolic-androgenic steroid use with other behavioral disorders: an analysis using directed acyclic graphs. *Psychological Medicine, 48*(15), 2601-2608.

Kleiger, R. E., Miller, J. P., Bigger Jr, J. T., & Moss, A. J. (1987). Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. *The American Journal of Cardiology, 59*(4), 256-262.

La Rovere, M. T., Bigger Jr, J. T., Marcus, F. I., Mortara, A., Schwartz, P. J., & Investigators, A. (1998). Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. *The Lancet*, 351(9101), 478-484.

Leifman, H., Rehmnan, C., Sjöblom, E., & Holgersson, S. (2011). Anabolic androgenic steroids—use and correlates among gym users—an assessment study using questionnaires and observations at gyms in the Stockholm region. *International Journal of Environmental Research and Public Health, 8*(7), 2656-2674.

Maior, A., Carvalho, A., Marques-Neto, S., Menezes, P., Soares, P., & Nascimento, J. (2013). Cardiac autonomic dysfunction in anabolic steroid users. *Scandinavian Journal of Medicine & Science in Sports, 23*(5), 548-555.

Maroccolo, M., Maior, A. S., Katayama, P. L., Ribeiro, G. (2013). Anabolic Steroid Treatment Induces Cardiac Autonomic Dysfunction in Rats: Time-Course of Heart Rate Variability. *American Journal of Biomedical Engineering, 3*(3): 54–62.

Neto, O. B., da Mota, G. R., De Sordi, C. C., Resende, E. A. M., Resende, L. A. P., da Silva, M. A. V., Maroccolo, M., Côrtes, R. S., de Oliveira, L. F., & da Silva, V. J. D. (2018). Long-term anabolic steroids in male bodybuilders induce cardiovascular structural and autonomic abnormalities. *Clinical Autonomic Research, 28*(2), 231-244.

Nieschlag, E., & Vorona, E. (2015). Doping with anabolic androgenic steroids (AAS): Adverse effects on non-reproductive organs and functions. *Reviews in Endocrine and Metabolic Disorders, 16*(3), 199-211.

Pereira-Junior, P. P., Chaves, E. A., Costa-e-Sousa, R. H., Masuda, M. O., de Carvalho, A. C. C., & Nascimento, J. H. (2006). Cardiac autonomic dysfunction in rats chronically treated with anabolic steroid. *European Journal of Applied Physiology, 96*(5), 487-494.

Picabea, J. M., Câmara, J., Nakamura, F. Y., & Yanci, J. (2021). Comparison of heart rate variability before and after a table tennis match. *Journal of Human Kinetics, 77*(1) 107–115.

Piccirillo, G., Ogawa, M., Song, J., Chong, V. J., Joung, B., Han, S., Magri, D., Chen, L. S., Lin, S.-F., & Chen, P.-S. (2009). Power spectral analysis of heart rate variability and autonomic nervous system activity measured directly in healthy dogs and dogs with tachycardia-induced heart failure. *Heart Rhythm, 6*(4), 546-552.

Rahnema, C., Crosnoe, L., & Kim, E. (2015). Designer steroids–over-the-counter supplements and their androgenic component: a review of an increasing problem. *Andrology, 3*(2), 150-155.

Ravé, G., Zouhal, H., Boullosa, D., Doyle-Baker, P. K., Saeidi, A., Abderrahman, A. Ben, & Fortrat, J. O. (2020). Heart rate variability is correlated with perceived physical fitness in elite soccer players. *Journal of Human Kinetics, 72*(1), 141–150.

Rocha, M., Aguiar, F., & Ramos, H. (2014). Anabolic androgenic steroids and other performance-enhancing drugs abuse - a silent epidemic. *Revista Portuguesa de Endocrinologia, Diabetes e Metabolismo, 9*(2): 98–105.

Rodrigues Junior, J. F., Silva, A. S., Cardoso, G. A., Silvino, V. O., Martins, M. C., & Santos, M. A. (2018). Androgenic-anabolic steroids inhibited post-exercise hypotension: a case control study. *Brazilian Journal of Physical Therapy, 22*(1), 77-81.

Sagoe, D., Molde, H., Andreassen, C. S., Torsheim, T., & Pallesen, S. (2014). The global epidemiology of anabolic-androgenic steroid use: a meta-analysis and meta-regression analysis. *Annals of Epidemiology, 24*(5), 383-398.

Santos, M. A. P., Oliveira, C. V. C., & de Silva, A. S. (2014). Adverse Cardiovascular Effects from the Use of Anabolic-Androgenic Steroids as Ergogenic Resources. *Substance Use & Misuse, 49*(9): 1132–1137.

Schwingel, P. A., Cotrim, H. P., Salles, B. R., Almeida, C. E., dos Santos Jr, C. R., Nachev, B., Andrade, A. R., & Zoppi, C. C. (2011). Anabolic-androgenic steroids: A possible new risk factor of toxicant-associated fatty liver disease. *Liver International, 31*(3), 348-353.
Seara, F. A., Arantes, P. C., Domingos, A. E., Barbosa, R. A., Olivares, E. L., Sudo, R. T., de Carvalho, A. C. C., & Nascimento, J. H. (2019). Cardiac electrical and contractile disorders promoted by anabolic steroid overdose are associated with late autonomic imbalance and impaired Ca2+ handling. Steroids, 148, 1-10.

Stanley, J., Peake, J. M., & Buchheit, M. (2013). Cardiac parasympathetic reactivation following exercise: implications for training prescription. Sports Medicine, 43(12), 1259-1277.

Vanberg, P., & Atar, D. (2010). Androgenic anabolic steroid abuse and the cardiovascular system. Doping in Sports: Biochemical Principles, Effects and Analysis, 411-457.

Vanderlei, L. C. M., Pastre, C. M., Hoshi, R. A., Carvalho, T. D. d., & Godoy, M. F. d. (2009). Basic notions of heart rate variability and its clinical applicability. Brazilian Journal of Cardiovascular Surgery, 24(2), 205-217.

Corresponding author:

Marcos Antônio Pereira dos Santos
Department of Biophysics and Physiology
Nucleus of Study in Physiology Applied to Performance and Health (NEFADS)
Rede Nordeste de Biotecnologia (RENOBIO) post-graduation program
Ministro Petrônio Portella Campus
Federal University of Piauí (UFPI), Teresina, Brazil
Phone: +55 (86) 98831-3654
E-mail address: marcosedfisio@gmail.com